These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29592882)

  • 1. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
    Li Y; Hickson JA; Ambrosi DJ; Haasch DL; Foster-Duke KD; Eaton LJ; DiGiammarino EL; Panchal SC; Jiang F; Mudd SR; Zhang C; Akella SS; Gao W; Ralston SL; Naumovski L; Gu J; Morgan-Lappe SE
    Mol Cancer Ther; 2018 May; 17(5):1039-1050. PubMed ID: 29592882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
    Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
    Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.
    Couch JA; Zhang G; Beyer JC; de Zafra CL; Gupta P; Kamath AV; Lewin-Koh N; Tarrant J; Allamneni KP; Cain G; Yee S; Ross S; Cook R; Tsai SP; Ruppel J; Ridgway JB; Paluch M; Hass PE; Franklin J; Yan M
    Clin Cancer Res; 2016 Mar; 22(6):1469-79. PubMed ID: 26589434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
    Phillips AC; Boghaert ER; Vaidya KS; Mitten MJ; Norvell S; Falls HD; DeVries PJ; Cheng D; Meulbroek JA; Buchanan FG; McKay LM; Goodwin NC; Reilly EB
    Mol Cancer Ther; 2016 Apr; 15(4):661-9. PubMed ID: 26846818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
    Zhang JF; Chen Y; Qiu XX; Tang WL; Zhang JD; Huang JH; Lin GS; Wang XF; Lin ZX
    Tumour Biol; 2016 Mar; 37(3):3797-805. PubMed ID: 26472724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
    Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Notch Pathway Promotes Flap Survival by Inducing Functional Neoangiogenesis.
    Abbas OL; Borman H; Terzi YK; Terzi A; Bayraktar N; Özkan B; Yazıcı AC
    Ann Plast Surg; 2015 Oct; 75(4):455-62. PubMed ID: 25180956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
    Kamath AV; Yip V; Gupta P; Boswell CA; Bumbaca D; Haughney P; Castro J; Tsai SP; Pacheco G; Ross S; Yan M; Damico-Beyer LA; Khawli L; Shen BQ
    MAbs; 2014; 6(6):1631-7. PubMed ID: 25484068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
    Zhou R; Wang S; Wen H; Wang M; Wu M
    Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β.
    Lacy SE; Wu C; Ambrosi DJ; Hsieh CM; Bose S; Miller R; Conlon DM; Tarcsa E; Chari R; Ghayur T; Kamath RV
    MAbs; 2015; 7(3):605-19. PubMed ID: 25764208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Guo Q; Gao B; Song R; Li W; Zhu S; Xie Q; Lou S; Wang L; Shen J; Zhao T; Zhang Y; Wu J; Lu W; Yang T
    Mol Cancer Ther; 2024 Oct; 23(10):1367-1377. PubMed ID: 38940283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.